HOME >> BIOLOGY >> NEWS
Braunschweig Prize 2003 for Molecular Cancer Therapy

Ten years ago the medic began working with the compound Imatinib that works against chronic myeloid leukemia (CML) and is commercially known as Glivec. Glivec blocks a protein that triggers the uncontrolled reproduction of white blood cells. "The name Brian Druker has become synonymous with a breakthrough in cancer therapy," said Braunschweig's mayor and chairman of the jury, Dr. Gert Hoffmann on the 8th of July after the vote of the council. Every year approximately 1700 people in Germany fall ill with CML. Some of the first patients to be treated with Glivec came from Germany.

Druker received his M.D. in 1981 from the University of California in San Diego. At Harvard Medical School he specialized in cancer research. Since 1993, Druker leads leukemia research at the Oregon Health & Science University Cancer Institute in Portland (USA). He is Investigator of the Howard Hughes Medical Institute and JELDWEN Chair of Leukemia Research. On the 27th of October he will accept the Braunschweig prize at the congress "Life in Tomorrow's World."

The American cancer researcher Prof. Dr. Brian Druker will be recognised for his research into molecular cancer ther-apy with the 50,000 Euro Braunschweig Prize, the highest research prize from a German city.

The 48-year-old medic is regarded as the pathfinder of the first tailor-made pill for the treatment of cancer. Ten years ago, in collaboration with the pharmaceutical company No-vartis, he identified the compound Imatinib, which in the meantime has become commercially available as Glivec. In contrast to chemotherapy that attacks both healthy and diseased cells, Imatinib targets a single protein that trig-gers the uncontrolled growth of white blood cells in chronic myeloid leukemia (CML). Every year approximately 1700 people in Germany fall ill with this blood cancer.

A recent study involving 1006 patients, comparing Glivec to standard therapy for CML, led by Druker, had to be stopped early because
'"/>

Contact: Jrgen Sperber
juergen.sperber@braunschweig.de
49-531-470-2212
Stadtverwaltung Braunschweig
8-Jul-2003


Page: 1 2

Related biology news :

1. Half-million dollar landmark achieved for the Methuselah Mouse Prize
2. Winner of 2004 EMBO Science Writing Prize announced
3. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
4. Stuart Lipton honored with Jung Prize for Medicine
5. 2004 Max Planck Research Prize for Martin Vingron and Eugene W. Myers
6. Scripps research scientist wins 2004 Koch Prize
7. Ohio State wetlands professor wins prestigious Water Prize
8. Tony Hunter and Raymond N. DuBois awarded Landon-AACR Prizes for Cancer Research
9. Leibniz Prizewinners 2004
10. Roderick MacKinnon wins 2003 Nobel Prize in Chemistry
11. Illinois professor wins Nobel Prize

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Braunschweig Prize for Molecular Cancer Therapy

(Date:11/18/2014)... , Nov. 18, 2014  The Secure ... Industry Association today jointly announce the formation of ... release of its Identity and Biometric Entry ... The Framework received official support from BORDERPOL, the ... to improve and provide expertise regarding border security, ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock Inc. ... solutions, and MorphoTrust USA (Safran), a ... today announced a strategic partnership to offer comprehensive ... vehicle administration (MVA), airport screening and financial services ... solutions, MorphoTrust serves consumers through a nationwide network ...
(Date:11/11/2014)... -- Forensicon, Inc., a Chicago -based digital ... promotion of Yaniv Schiff from Senior Computer ... new role as Director, he will lead company efforts ... and provide leadership within the company,s digital forensics practice ... Schiff joined Forensicon in 2006 and ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
(Date:11/26/2014)... (PRWEB) November 25, 2014 SonaCare ... Focused Ultrasound (HIFU) devices, recently participated in the ... Renal Mass 360° .” Key opinion leaders in ... advances related to small renal masses while attendees ... different ablative technologies in hands-on labs. Attendees at ...
(Date:11/26/2014)... OH (PRWEB) November 25, 2014 Miles ... has joined the Graphel Carbon Products team as Sales/Marketing ... sales, marketing, and customer service for the graphite industry. ... Miles to our team,” stated Dave Trinkley, VP of ... “His wide range of experience in the graphite industry, ...
(Date:11/26/2014)... , Nov. 25, 2014 Bio-Techne Corporation ... has appointed Robert Gavin to serve in ... the Protein Platforms Division.  Mr. Gavin will be responsible ... segment, which includes the ProteinSimple business acquired in July ... San Jose, California -based ProteinSimple develops ...
(Date:11/24/2014)...  Last week, Representatives Gus Bilirakis ... a bold bipartisan step on behalf of patients ... Original co-sponsors of the legislation include Representatives McCaul ... drug makers and innovators to "repurpose" major market ... which opens the door to the development of ...
Breaking Biology Technology:SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
Cached News: